Publications
B Cells, DC Cells, NK Cells, Other, Treg Cells
Publication Date: September 7, 2023
Small extracellular vesicles (sEV) are released by essentially every type of immune cell, and their cargo reflects the biology of the cell of origin. This review organizes the literature by cell group: neutrophils, eosinophils, basophils, mast cells and NK cells; dendritic cells, macrophages, myeloid-derived suppressor cells and B cells; and CD8+, CD4+, regulatory and follicular helper T cells. Vesicles of 50 to 150 nm carry proteins, lipids and miRNAs that can promote or dampen inflammation, kill tumor cells, transfer antigen or suppress T cells. Examples include cytotoxic NK-derived sEV, CD73-bearing Treg and CD8+ T cell sEV, and MDSC sEV that ameliorated colitis and arthritis in mice.…
Publications
CAR T Cells
Publication Date: September 5, 2023
Point-of-care manufacturing of autologous CAR T cells within academic healthcare systems is presented as a way to widen patient access and cut costs relative to the centralized commercial model, provided quality can be standardized. Commercial products total nearly $500,000 and patients may wait up to 3 weeks for a manufacturing slot. Decentralized production can shorten manufacturing to 7-10 days instead of 14 and may cost as little as $35,000 when a sponsor supplies the vector. Closed automated platforms such as CliniMACS Prodigy and Cocoon support this model. Main hurdles are GMP vector supply, trained staff, quality control, facilities and financing.
Publications
TIL Cells
G-Rex®6 Well Plate
Publication Date: September 4, 2023
Adding an oncolytic adenovirus that encodes a variant IL-2 (Ad5/3-E2F-d24-vIL2, also called TILT-452) to autologous tumor-infiltrating lymphocytes improved cytotoxic activity against advanced ovarian cancer. Tumor digests from twelve patients, mostly stage IVB, were co-cultured with autologous TILs and virus. Real-time impedance measurement showed consistent cancer cell killing in all samples except one, compared with TILs alone. In a patient-derived xenograft mouse model, the combination gave the best tumor control, with all treated animals responding until day 12, and raised granzyme B in CD4+ T, CD8+ T and NK cells. Regulatory T cells also increased in these tumors. The sample number w…
Publications
NK Cells
G-Rex®6 Well Plate
Publication Date: August 30, 2023
Expanding human NK cells first with K562 feeder cells carrying membrane-bound IL-21 and then with feeders carrying membrane-bound IL-15 combined high yield with strong antitumor function. Purified NK cells from healthy donors were stimulated with irradiated feeders on day 0 and day 10 and tested on day 20. Feeders with mbIL21 alone gave 15,000- to 700,000-fold expansion versus about 1,000- to 15,000-fold with mbIL15 alone, but weaker antitumor activity by every measure except ADCC. The mbIL21-then-mbIL15 sequence gave far higher yields than mbIL15 alone, killed tumor lines resistant to fresh NK cells, and matched mbIL15-only NK cells in the Raji lymphoma and RPMI-8226 myeloma xenograft mo…
Publications
NK Cells
Publication Date: August 29, 2023
Messenger RNA delivered in lipid nanoparticles can turn expanded natural killer cells into functional CAR-NK cells without viral vectors. NK cells isolated from donor blood were expanded more than 8000-fold on K562 feeder cells expressing 4-1BB ligand and membrane-bound IL-21, then transfected with CD19-CAR or BCMA-CAR mRNA-LNPs, yielding 78.8% and 95.3% CAR-positive cells. The CAR-NK cells killed myeloma lines (RPMI8226, MM1S) and leukemia lines (Daudi, Nalm-6) and secreted more IFN-gamma and Granzyme B than unmodified NK cells. In NSG mice carrying Nalm-6 leukemia, CD19-CAR-NK cells, injected four times, blocked tumor growth significantly more than unmodified NK cells by day 15.
Publications
T-Cells
G-Rex®100M-CS, G-Rex®24 Well Plate, G-Rex®500M-CS, G-Rex®6 Well Plate, G-Rex®6M Well Plate
Publication Date: August 23, 2023
A good manufacturing practice-compliant, scalable process corrected the CD40LG gene in human CD4+ T cells by Cas9 ribonucleoprotein editing with an integrase-defective lentiviral vector donor template, shortening the protocol from 21 to 13 days. Delivering the vector at day 2 before electroporation, together with LentiBoost, gave optimal editing efficiency, and immunomagnetic enrichment of LNGFR-positive cells on day 6 produced a nearly pure product with 46-fold cumulative growth. Patient cells were edited with similar or better efficiency and kept stem cell memory and central memory phenotypes. Edited cells engrafted in NSG mice with stable editing in blood, bone marrow and spleen. At fu…
Publications
CAR T Cells, Other
Publication Date: August 22, 2023
Cytokine-induced killer (CIK) cells offer a practical alternative to CAR-T cells for patients who cannot access CAR-T therapy, because they avoid viral-vector engineering and can be made in local academic GMP facilities. This review compares the two platforms. CAR-T therapy faces high cost, centralized manufacturing and CRS/ICANS toxicity, whereas CIK cells kill tumors in an MHC-unrestricted manner via NKG2D and rarely cause GvHD. Reagent costs are estimated below €5,000 per batch, and 30 ml of blood can yield enough cells for repeated treatment. G-Rex® expansion gave a 752-fold increase. The authors propose CIK cells alongside, not instead of, CAR-T cells.
Application Notes
CAR T Cells, NK Cells
Publication Date: July 28, 2023
Co-culturing gene-edited CAR T cells with irradiated CD3-specific CAR NK-92 cells during expansion stripped residual T cell receptor-positive cells down to below 0.01 per cent, a 45-fold improvement on magnetic separation. Four CD3- or TCR-directed CAR constructs were knocked into the AAVS1 locus of NK-92 cells, and three killed more than 80 per cent of target cells within four hours at the highest ratio while sparing edited cells. Run in G-Rex® 6-well plates from day 5, two spaced co-cultures left 0.026 and 0.007 per cent contaminating cells on day 14 against 3.1 per cent for magnetic separation, roughly tripled yield, and preserved cytotoxicity and phenotype.
Publications
CAR T Cells
G-Rex®100M, G-Rex®24 Well Plate, G-Rex®6 Well Plate
Publication Date: June 26, 2023
Homology-independent targeted insertion (HITI) with CRISPR/Cas9 and nanoplasmid DNA placed an anti-GD2 CAR into the TRAC locus of primary human T cells and, on average, gave about threefold higher CAR-T cell yields than an HDR template with comparable insertion rates. Adding methotrexate-driven CEMENT selection of a DHFR-FS marker from day 3 raised purity to 86.6–91.4%, and at day 14 enriched cultures reached 80–85% CAR-positive cells. Clinical-scale runs with three donors produced doses of 5.5 × 10^8 to 3.6 × 10^9 CAR-positive T cells in a 14-day process. Average on-target copy number was 1.08, no off-target editing was detected, and knock-in cells matched virally transduced cells in phe…
Publications
γδ T
Publication Date: June 16, 2023
Cord blood γδ T cells expanded far better than adult peripheral blood γδ T cells in a feeder-based rapid expansion protocol, and single-cell sequencing showed that their Vδ2− and Vδ2+ subsets follow different differentiation paths. Cord blood γδ T cells were stimulated with irradiated PBMCs and EBV-transformed feeder cells, with IL-2, IL-15 and IL-21, and reached an average 2.5 × 10^6-fold expansion in 3 weeks, versus minimal expansion of peripheral blood cells at day 14. Cells developed into cytotoxic, tissue-resident memory precursor-like and antigen-presenting-like states. Most Vδ1+ and Vδ3+ clones were biased toward cytotoxic cells, whereas Vδ2+ clones, especially Vγ9+Vδ2+, showed a m…
Publications
TCR T Cells, TIL Cells
G-Rex®10, G-Rex®100M
Publication Date: June 15, 2023
Loss of CD58 on melanoma cells lets tumors escape T cell attack, and the same loss raises PD-L1 through the shared stabilizer CMTM6. In co-cultures of patient-derived melanoma cells with autologous TILs, CD58 knockout reduced killing and IFN-γ release, while re-expressing either CD58 isoform restored both; blocking CD2 or CD58 prevented the rescue. In partly humanized mice, CD58-knockout tumors showed no responders among eight animals given TIL transfer and about 100-fold fewer CD8+ TILs. A genome-wide CRISPR screen and IP-mass spectrometry identified CMTM6 as a CD58 binding partner; CD58 and PD-L1 compete for CMTM6, so CD58 loss stabilizes PD-L1 and reduces its lysosomal degradation. An…
Publications
TCR T Cells, TIL Cells
G-Rex®24 Well Plate
Publication Date: May 31, 2023
Sorting CD8+ tumor-infiltrating lymphocytes that co-express CD39, PD-1 and TIGIT ("triple positive" TIL) offers a rapid way to capture neoantigen-reactive T-cell receptors directly from metastatic epithelial tumor digests. Clone frequencies in the sorted population correlated strongly with a single-cell transcriptomic neoantigen-reactive state. Of 120 unique CDR3β sequences from five tumors, 39 were already known or met criteria for reconstruction, and reconstruction and testing showed that at least 39.5% of the sorted-population TCRs were neoantigen-reactive or tumor-reactive. After rapid expansion, however, reactive clones were lost or functionally impaired: expanded cells from three of…
No manuscripts match your filters.